Yenos Analytical Launches Multi-Cancer Early Detection Urine Test
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read MorePosted by CLP Edit Staff | Dec 19, 2025 | Cancer, Company News, Molecular Diagnostics |
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read MorePosted by Alyx Arnett | Dec 17, 2025 | Diagnostic Technologies |
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
Read MorePosted by CLP Edit Staff | Dec 9, 2025 | Cancer |
Research analyzing cell-free DNA fragmentation patterns in healthy individuals reveals physiological confounders that could improve test accuracy.
Read MorePosted by CLP Edit Staff | Dec 3, 2025 | Prostate |
The test receives premarket approval as an aid in biopsy decision-making for men 50 and older with elevated PSA levels.
Read MorePosted by CLP Edit Staff | Nov 20, 2025 | Prostate |
The whole-genome test combines data from 7 million genetic markers with clinical risk factors to provide individualized 10-year and lifetime risk assessments.
Read More